Acadia Pharmaceuticals | ACAD - Actif À Court Terme





Actif À Court Terme Changement Date
Acadia Pharmaceuticals USD 1.27B 43.88M 2026-09
ALKERMES USD 1.58B 57.83M 2026-09
Alnylam Pharmaceuticals USD 5.11B 492.49M 2026-09
Biogen USD 7.58B 278.7M 2026-09
BioMarin Pharmaceutical USD 3.92B 50.99M 2026-09
Bristol-Myers Squibb USD 29.77B 1.19B 2026-09
Cara Therapeutics USD 23.13M 2.2M 2026-09
Corcept Therapeutics USD 533.87M 94.2M 2026-09
Cytokinetics USD 1.19B 21.34M 2026-09
Eisai JPY 866.82B 16.2B 2026-09
Eli Lilly USD 65.26B 591M 2026-09
Incyte USD 5.52B 505.2M 2026-09
J&J USD 56.35B 3.42B 2026-09
Moderna USD 7.34B 1.53B 2026-09
Neurocrine Biosciences USD 2.01B 370.7M 2026-09
Pfizer USD 45.01B 3.65B 2026-09
Prothena USD 273.86M 18.15M 2026-09
PTC Therapeutics USD 2.54B 79.58M 2026-09
Sarepta Therapeutics USD 2.27B 49.06M 2026-09
Ultragenyx Pharmaceutical USD 544M 62M 2026-09
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12
Vertex Pharmaceuticals USD 11.69B 857.4M 2026-09